US4041153A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and pharmaceutical preparation for the treatment of hypercholesterolaemia
Assignee: Bristol Myers Co
•
Filing: 1975-06-02
•
Granted: 1977-08-09
•
Expires: 1995-06-02
Abstract
Abstract A composition for treatment of hypercholesterolemia contains clofibrate or a clofibrate derivative, a metal ion contributing compound which forms substantially insoluble metal bile acid salts and, optionally, a basic anion exchange resin. The composition components combine to give synergistic effect.
Inventors
- 👤 Alan N. Howard
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:33
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K31/00; A61K31/21; A61K31/215; A61K33/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
83 words
A pharmaceutical composition for use in the treatment per os of hypercholesterolemia, which comprises a hypocholesteremic effective amount of (a) a compound selected from p-chlorophenoxyisobutyric acid, the methyl, ethyl, propyl or butyl ester thereof or a sodium, potassium, calcium, magnesium, aluminum, zinc, bismuth or iron salt thereof, and (b) an ingestible non-toxic bismuth salt capable of dissolution in human gastrointestinal juices, the total amount of non-toxic metal being from 3.2 to 90 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 2
Dependent Claim
83 words
A pharmaceutical composition for use in the treatment per os of hypercholesterolemia, which comprises a hypocholesteremic effective amount of (a) a compound selected from p-chlorophenoxyisobutyric acid, the methyl, ethyl, propyl or butyl ester thereof or a sodium, potassium, calcium, magnesium, aluminum, zinc, bismuth or iron salt thereof, and (b) an ingestible non-toxic bismuth salt capable of dissolution in human gastrointestinal juices, the total amount of non-toxic metal being from 3.2 to 90 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 3
Dependent Claim
29 words
A composition according to claim 1 wherein the total amount of non-toxic metal is from 4 to 15 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 4
Dependent Claim
39 words
A composition according to claim 1 wherein there is also present one or more ingestible non-toxic basic anion exchange resins, there being from 50 to 8000 grams of resin per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 5
Dependent Claim
20 words
A composition according to claim 3 wherein the anion exchange resin is selected from cholestyramine, colestipol or poly-[2-(diethylamino)ethyl]-polyglycerylene dextran hydrochloride.
Claim 6
Dependent Claim
12 words
A composition according to claim 1 comprising ethyl p-chlorophenoxyisobutyrate and bismuth hydroxide.
Claim 7
Independent Claim
90 words
A method for the treatment of hypercholesterolemia, in which there is administered to the patient per os a hypocholesteremic effective dose of a pharmaceutical composition comprising (a) a compound selected from p-chlorophenoxyisobutyric acid, the methyl, ethyl, propyl or butyl ester thereof or a sodium, potassium, calcium, magnesium, aluminum, zinc, bismuth or iron salt thereof, and (b) an ingestible non-toxic bismuth salt capable of dissolution in human gastrointestinal juices, the total amount of non-toxic metal being from 3.2 to 90 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 8
Independent Claim
90 words
A method for the treatment of hypercholesterolemia, in which there is administered to the patient per os a hypocholesteremic effective dose of a pharmaceutical composition comprising (a) a compound selected from p-chlorophenoxyisobutyric acid, the methyl, ethyl, propyl or butyl ester thereof or a sodium, potassium, calcium, magnesium, aluminum, zinc, bismuth or iron salt thereof, and (b) an ingestible non-toxic bismuth salt capable of dissolution in human gastrointestinal juices, the total amount of non-toxic metal being from 3.2 to 90 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 9
Dependent Claim
31 words
A method according to claim 6 wherein the composition contains a total amount of non-toxic metal from 4 to 15 equivalents per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 10
Dependent Claim
39 words
A method according to claim 6 wherein the composition also contains one or more ingestible non-toxic basic anion exchange resins, there being from 50 to 8000 grams of resin per mole of p-chlorophenoxyisobutyric acid or ester or salt thereof.
Claim 11
Dependent Claim
20 words
A method according to claim 8 wherein the anion exchange resin is selected from cholestyramine, colestipol or poly-[2-(diethylamino)ethyl]-polyglycerylene dextran hydrochloride.
Claim 12
Dependent Claim
42 words
A method according to claim 6 wherein the composition comprises ethyl p-chlorophenoxyisobutyrate and bismuth hydroxide, said composition being administered in an amount sufficient to provide a daily dosage of about 1.5 g. of ethyl p-chlorophenoxyisobutyrate and about 2.0 g. of bismuth hydroxide.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-08-08 | 1981-02-07 | 1981-08-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-08-08 | 1985-02-07 | 1985-08-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-08-08 | 1989-02-07 | 1989-08-09 | $7700.00 | Window Closed / Lapsed |